F-X Mahon

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Mette Ilander, Ulla Olsson‐Strömberg, Heinrich Schlums et al. · Leukemia · 2016 · 247 citations · Full text

Medicine, Hematology, Immunology +14

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)

Franck E. Nicolini, Sélim Corm, Q.H. Le et al. · Leukemia · 2006 · 203 citations

Life Sciences, Genetics, Hematology +15

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

Andreas Hochhaus, Gianantonio Rosti, Nicholas C.P. Cross et al. · Leukemia · 2015 · 107 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +8

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial

S. Prey, Khaled Ezzedine, A. Doussau et al. · British Journal of Dermatology · 2012 · 105 citations

Medicine, Dermatology, Dermatopathology +8

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

Aj Tipping, F-X Mahon, G Zafirides et al. · Leukemia · 2002 · 88 citations

Medicine, Oncology, Pharmacology +10